LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Strona główna・Stock List・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Closed

4.29 -4.24

Buy Sell

Overview

Share price change

24h

Current

Min

4.29

Max

4.33

Key metrics
By Trading Economics
Income	4M -3.8M
Sales	522K 1.1M
EPS	-0.014
Profit margin	-357.374
Employees	44
EBITDA	-1.1M -8.8M

Dividends
By Dow Jones
Next Earnings	13 maj 2026

Market Stats
By TradingEconomics
Market Cap	12M 851M
Previous open	8.53
Previous close	4.29

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

3.255 / 3.365 Support & Resistance

Arbutus Biopharma Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 mar 2026, 17:33 UTC

Major News Events

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mar 2026, 17:00 UTC

Major News Events

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mar 2026, 16:03 UTC

Major News Events

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29 mar 2026, 23:47 UTC

Market Talk

Major News Events

Gold Falls Amid Rising Inflation Fears -- Market Talk

29 mar 2026, 23:46 UTC

Market Talk

Major News Events

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29 mar 2026, 23:35 UTC

Market Talk

Major News Events

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29 mar 2026, 23:23 UTC

Market Talk

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29 mar 2026, 22:34 UTC

Market Talk

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29 mar 2026, 22:09 UTC

Market Talk

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29 mar 2026, 21:06 UTC

Market Talk

Major News Events

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29 mar 2026, 21:03 UTC

Market Talk

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29 mar 2026, 21:01 UTC

Market Talk

Major News Events

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29 mar 2026, 09:30 UTC

Acquisitions, Mergers, Takeovers

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28 mar 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

27 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27 mar 2026, 19:16 UTC

Market Talk

Major News Events

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mar 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mar 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mar 2026, 19:03 UTC

Market Talk

Major News Events

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 19:02 UTC

Market Talk

Major News Events

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mar 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mar 2026, 17:36 UTC

Major News Events

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mar 2026, 17:34 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mar 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mar 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mar 2026, 16:32 UTC

Market Talk

Major News Events

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mar 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27 mar 2026, 15:43 UTC

Market Talk

Major News Events

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mar 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Peer Comparison

Price change

Arbutus Biopharma Corp Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Arbutus Biopharma Corp - Dist in the past 3 months.

Technical Score

By Trading Central

3.255 / 3.365Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.